This year has been unlike any other, but at HEMEX we have continued with a positive spirit through it all. In this article, we want to take a look back at 2020 as we look ahead to all that we can accomplish next year.
We started the year by offering a compelling workshop in collaboration with our external IP Consultants from Vossius & Partner that provided information regarding Intellectual Property protection. We were thrilled to welcome Inura Medical to our growing list of portfolio companies, and when the W.A. De Vigier Foundation “TOP 60” kicked off, we were very proud to see our portfolio companies Annaida Technologies, LiVET, and Juvabis make it to the Top 16.
In April, our portfolio company GeoHealthApp GmbH launched a Beta version in various countries that could help stop the spread of COVID-19. We were delighted to welcome Hi-D Imaging AG to our growing list of portfolio companies, and Annaida Technologies closed CHF 1 M in a seed financing round led by HEMEX. Some days later, we celebrated another closing of a seed financing round, this time for LiVET led by a private investor. In May, the new reliable, fast, and cost effective COVID-19 testing kits were launched by ender diagnostics AG. Shortly after that, we became part of a consortium originating from the M4IVD association, including Swiss TPH, University of Basel, ETH Zurich, CSEM, BioInitials and EM. The consortium received a significant grant from the Botnar Research Center for Child Health (BRCCH) to combat COVID-19 by developing an at-home saliva-based antigen/antibody test.
Scailyte closed CHF 3.1 M pre-series A financing round and was selected among the 12 finalists for the Nature Research Spinoff Prize. The first rapid test from ender diagnostics was CE -certified and ARTIDIS announced promising data from their first prospective study conducted at the Breast Cancer Center in Basel. Resistell received EUR 2.5M from the EIC Accelerator Grant plus an Equity Financing, and Sleepiz AG announced CE clearance for its first medical product; Sleepiz One. Moreover, the “Top 100 Swiss Start-up” celebrated a very special edition for us, as numerous Start-ups from our portfolio made it onto the list; ASPIVIX, Scailyte, Annaida Technologies, Resistell AG, and Sleepiz. In September, BioReperia joined an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program, and Inura was selected for the loan “100 fürs Baselbiet” from BLKB and received a total of 500,000 CHF. Last but not least, AMT Medical secured EUR 10 million in funding during these uncertain times.
As our team started growing rapidly, we decided to initiate our Diversity Series with which we have learnt a lot of funny facts about our colleagues. When in October the positive number of the COVID-19 pandemic started picking up again, the second lockdown started. This past year has been unique in our HEMEX history. It has also been very successful, exciting, and meaningful as the HEMEX family has come together to support each other. We have learnt that connection as a team does not have anything to do with being in the same space but with the ability to share moments, emotions, beliefs, values, and a purpose.
HEMEX is committed to changing the future of healthcare by guiding the most promising European start-ups through each and every step to bring innovative pharmaceuticals, medical devices and in vitro diagnostics to the market. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure start-ups have access to a wide range of tailored products, practical solutions and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare. For more information, visit https://hemex.ch/